Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MAM domain-containing protein 4 (MAMDC4)
- Target
- MAMDC4
- Molecular classification
- Other (not a receptor, channel, transporter, transcription factor, or enzyme with well-established catalytic activity), Single-pass transmembrane protein, MAM domain-containing protein family (protein with extracellular adhesive type MAM domains)
01
Overview
MAM domain-containing protein 4 (MAMDC4) is a single-pass transmembrane glycoprotein present in human cells, characterized by multiple extracellular MAM domains that probably function in adhesion and protein–protein interactions. It is predicted to be involved in the sorting and selective transport of receptors and ligands across polarized epithelial cells, participating in protein transport and possibly in the Wnt signaling pathway or protein localization mechanisms. While genetic alterations in MAMDC4 are associated with rare forms of Von Willebrand disease, there is currently no direct evidence supporting its role as a target for therapeutic drugs or as a clinical biomarker. No safety concerns or drug interactions are known. The protein is catalogued by several aliases and external identifiers in genomics and protein databases.
- Other names
- Apical endosomal glycoproteinAEGPUNQ3001/PRO9742DKFZp434M1411EDTBEndotubinApical early endosomal glycoprotein precursorApical early endosomal glycoproteinHGNC: 24083Q6UXC1 (UniProtKB/Swiss-Prot)
02
Mechanism of action
None. There are no drugs known to target MAMDC4; therefore, mechanism(s) of action are not established.
03
Biological functions
Sorting and selective transport of receptors and ligands across polarized epitheliaProtein transportMay act upstream of or within the Wnt signaling pathway and protein localization to the nucleus
04
Disease associations
Associated (genetically) with Von Willebrand disease type 2 and type 3 (this is correlative, not necessarily causative)No direct evidence for involvement in major therapeutic categories such as cancer, inflammation, infection, neurodegeneration, or cardiovascular disease from current sources
05
Safety considerations
None described in the literature or databases. No clinical development or drug targeting implies no reported safety issues
06
Interacting drugs
None reported or annotated in pharmacological databases or the literature
1 more in the full profile.
07
Biomarkers
None known or established for patient selection or efficacy monitoring for this molecule
Beyond the preview
Go deeper on MAM domain-containing protein 4 (MAMDC4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAM domain-containing protein 4 (MAMDC4).